{"id":270253,"date":"2026-09-07T08:20:11","date_gmt":"2026-09-07T08:20:11","guid":{"rendered":"https:\/\/www.europesays.com\/ee\/270253\/"},"modified":"2026-09-07T08:20:11","modified_gmt":"2026-09-07T08:20:11","slug":"geenikaarid-voivad-halva-kolesterooli-pooleks-loigata-uhe-ravikorraga-tervis","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ee\/270253\/","title":{"rendered":"Geenik\u00e4\u00e4rid v\u00f5ivad halva kolesterooli pooleks l\u00f5igata \u00fche ravikorraga | Tervis"},"content":{"rendered":"<p>Uudne geeniravi v\u00f5ib aidata k\u00f5rget kolesteroolitaset ohjata \u00fcheainsa ravikorraga. V\u00e4rskes esimese faasi <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2609825\" rel=\"nofollow noopener\" target=\"_blank\">uuringus<\/a> langetas maksarakkude geene muutnud CTX310 patsientidel LDL-kolesterooli taset ligi poole v\u00f5rra ning toime p\u00fcsis v\u00e4hemalt aasta.<\/p>\n<p>Kujutlege, et k\u00f5rge kolesteroolitaseme ohjeldamiseks ei pea enam iga p\u00e4ev ravimeid v\u00f5tma. Selle asemel v\u00f5ib piisata \u00fchest infusioonist, mis muudab p\u00fcsivalt inimese p\u00e4rilikkusainet. V\u00e4rske uuring n\u00e4itab, et uudne geeniravim langetab edukalt halva kolesterooli ja teiste vererasvade taset ning toime p\u00fcsib ka aasta p\u00e4rast ravimini manustamist.\u00a0<\/p>\n<p>Sellise tulemuseni j\u00f5udsid USA, Austraalia ja Uus-Meremaa teadlased, kes katsetasid ravimikandidaati CTX310. Uuringus osales 15 t\u00e4iskasvanut, kellel oli raskesti kontrollitav k\u00f5rge kolesteroolitase v\u00f5i m\u00f5ni muu t\u00f5sine rasvaainevahetuse h\u00e4ire.<\/p>\n<p>Tulemused olid k\u00f5ige ilmekamad suurima ravimiannuse saanud osalejatel. Neljal patsiendil langes madala tihedusega lipoproteiini ehk LDL-kolesterooli tase aastaga keskmiselt ligi 53 protsenti. Lisaks v\u00e4henes neil s\u00fcdame-veresoonkonnahaiguste riski suurendavate trigl\u00fctseriidide ehk veres ringlevate rasvade tase 48 protsenti.<\/p>\n<p>Patsiendid talusid ka ravi h\u00e4sti: aasta jooksul ei ilmnenud ei m\u00fcrgistusn\u00e4hte ega ohtlikke k\u00f5rvaltoimeid.<\/p>\n<p>Kuidas asi siis toimib? P\u00f5him\u00f5tteliselt j\u00e4ljendasid teadlased inimese bioloogias juba esinevat n\u00e4htust. CRISPR-tehnoloogia ehk geenik\u00e4\u00e4ride abil l\u00fclitasid nad maksarakkudes v\u00e4lja \u00fche konkreetse geeni. M\u00f5nel inimesel on see geen loomu poolest vigane ning kaitseb neid veresoonte lupjumise eest. Uus teraapia matkibki seda kaasas\u00fcndinud kaitsemehhanismi. Ravi tekitab maksas p\u00fcsiva geneetilise muutuse, mis aitab kehal vererasvade taset v\u00e4hendada.<\/p>\n<p>Ajakirjas <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2609825\" target=\"_blank\" rel=\"noopener nofollow\">New England Journal of Medicine<\/a> ilmunud artiklis t\u00f5devad uurijad, et tulemused toetavad CTX310 sobivust \u00fchekordseks ja pikaajaliseks raviks. Samas on ravi ohutuse ja pikaajalise toime l\u00f5plikuks hindamiseks vaja l\u00e4bi viia lisauuringuid.<\/p>\n<p>Teadusuudised on Vikerraadios eetris esmasp\u00e4evast reedeni ca kell 8.35 ja laup\u00e4eval ca kell 8.25.<\/p>\n","protected":false},"excerpt":{"rendered":"Uudne geeniravi v\u00f5ib aidata k\u00f5rget kolesteroolitaset ohjata \u00fcheainsa ravikorraga. V\u00e4rskes esimese faasi uuringus langetas maksarakkude geene muutnud CTX310&hellip;\n","protected":false},"author":2,"featured_media":270254,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[80],"tags":[26,27,10976,37,33,35,34,36,31,32,1863,10982,23591,21,11862,28,29,95,19,25,24038,308,23,24,22,20,37380,30,92,93,94],"class_list":["post-270253","post","type-post","status-publish","format-standard","has-post-thumbnail","category-maailm","tag-breaking-news","tag-breakingnews","tag-crispr","tag-ee","tag-eesti","tag-eesti-keel","tag-estonia","tag-estonian","tag-featured-news","tag-featurednews","tag-geenid","tag-geenikaarid","tag-geeniravi","tag-headlines","tag-kolesterool","tag-latest-news","tag-latestnews","tag-maailm","tag-news","tag-populaarseimad-lood","tag-rasv","tag-tervis","tag-top-stories","tag-topstories","tag-uldised-uudised","tag-uudised","tag-veri","tag-viimased-uudised","tag-world","tag-world-news","tag-worldnews"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ee\/117228786501787024","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts\/270253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/comments?post=270253"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts\/270253\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/media\/270254"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/media?parent=270253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/categories?post=270253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/tags?post=270253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}